Northwestern University Study Suggests RNA Therapy Could Treat Rare Childhood Epilepsy Before Birth

Northwestern University researchers find RNA therapy can calm KCNT1 epilepsy activity in utero, potentially preventing brain damage before birth.

By: AXL Media

Published: May 1, 2026, 11:27 AM EDT

Source: Information for this report was sourced from EurekAlert

A Potential Shift Toward Prenatal Intervention for Severe Epilepsy

Medical researchers at Northwestern University have identified a critical window for treating rare, treatment-resistant epilepsy that may begin months before a child is born. A study published in Nature Communications reveals that intervention for KCNT1-related disorders could potentially start as early as 15 weeks gestation, representing a significant shift from reactive symptom management to proactive, prophylactic care. According to Richard Smith, assistant professor at Northwestern University Feinberg School of Medicine, the goal is to establish therapeutic models that prevent brain damage during its normal developmental timeline rather than attempting to reverse harm after birth.

The Destructive Nature of KCNT1 Gene Mutations

The specific disorder, known as KCNT1-related epilepsy, affects roughly 3,000 individuals across the globe and is notorious for its resistance to conventional pharmaceutical treatments. Children suffering from epilepsy of infancy with migrating focal seizures, or EIMFS, can experience up to 100 seizures in a single day, leading to severe developmental delays and a high risk of premature death. By utilizing brain cells grown in laboratory settings from patients with these mutations, scientists were able to observe the excessive electrical activity and hyper-excitation that characterize the disease, providing a clearer biological map of why standard interventions often fail.

Testing RNA-Based Antisense Oligonucleotides on Developing Neurons

To combat this electrical instability, the research team employed an experimental RNA-based therapy known as an antisense oligonucleotide, or ASO. This treatment is specifically designed to reduce the activity of the KCNT1 gene, effectively dampening the abnormal electrical currents within excitatory neurons. The study confirmed that the ASO therapy was successful in reducing excessive firing in lab-grown brain cells that were equivalent in development to the middle of pregnancy, specifically between 15 and 21 weeks. This laboratory success establishes a foundational clinical basis for applying such genetic therapies during the perinatal period.